Annual Congress Copenhagen 2005

Saturday, 17.09.2005
Sunday, 18.09.2005
Monday, 17.09.2005
Tuesday, 20.09.2005
Wednesday, 21.09.2005

Citations should be made in the following way: Authors. Title. Eur Respir J 2005; 26: Suppl. 49, abstract number.

Material from 2005:

4063 Abstracts
739 Slide presentations
213 Webcasts
93 Handouts

Material from 2005: Show

Novel therapies for asthma

Poster Discussion
Chairs: M. Molimard (Bordeaux, France), D. Ukena (Bremen, Germany)

Download all media

Quality of life of stable dose treatment with salmeterol/fluticasone (SFC) compared with adjustable maintenance dosing (AMD) with formoterol/budesonide (FBC) D. Price, A. E. Williams, S. Yoxall, A. Gauthier (Aberdeen, Greenford, United Kingdom)
R411 treatment reduces asthma exacerbations and attenuates FEV₁ fall following steroid withdrawal in moderate asthma A. D. Rames, W. W. Busse, L. Renzetti, A. S. Nayak (Basel, Switzerland; Madison, Nutley, Peoria, United States Of America)
As-needed treatment with a β₂-agonist or a β₂-agonist/ corticosteroid combination in mild intermittent asthma (SOMA) T. Haahtela, K. Tamminen, P. Malmberg, J. Karjalainen, H. Ylä-Outinen, O. Zetterström, T. Ekström, O. Selroos (Helsinki, Finland; , ; Linköping, Sweden)
Ciclesonide decreases exhaled breath nitric oxide and rapidly reduces airway responsiveness to adenosine monophosphate in asthma patients E. M. Erin, R. Engelstätter, M. Hellwig, T. T. Hansel, P. J. Barnes (London, United Kingdom; Konstanz, Germany)
Improving asthma therapy through targeting more effective control of inflammation - a European consensus S. Holgate, for the European Consensus Conference (Southampton, United Kingdom)
Indacaterol: the first once-daily β₂-agonist with 24-hour bronchodilation K. M. Beeh, E. Derom, F. Kanniess, R. Cameron, A. van As (Wiesbaden, Hamburg, Germany; Ghent, Belgium; Horsham, United Kingdom; East Hanover, United States Of America)
Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β₂-agonist, in patients with mild asthma A. Tarral, N. Fauchoux, H. Knight, S. Perry, J. Wood, L. Brookman (Paris, Rennes, France; , ; Horsham, United Kingdom)
Single-dose indacaterol, a novel 24-hour β₂-agonist, is well tolerated in patients with mild asthma T. Duvauchelle, B. Elharrar, H. Knight, A. Krebbs-Brown, S. Perry, P. Freeman, L. Brookman (Paris, France; Basel, Switzerland; Horsham, United Kingdom)
Cardiovascular safety of indacaterol, a novel 24-hour β₂-agonist, in patients with stable asthma A. Chuchalin, A. Tsoi, K. Richter, R. Cameron, W. Bao, A. van As (Moscow, Russian Federation; Grosshansdorf, Germany; Horsham, United Kingdom; East Hanover, United States Of America)
Indacaterol, a novel β₂-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study F. Kanniess, R. Cameron, R. Owen, M. Higgins (Grosshansdorf, Germany; Horsham, United Kingdom)
Randomized, placebo-controlled studies of onset and duration of single-dose protection against exercise-induced bronchoconstriction (EIB) by montelukast G. Philip, J. van Adelsberg, D. S. Pearlman, C. Villaran, T. Loeys, O. Johnson, S. Cupo, T. F. Reiss (Rahway, Denver, United States Of America; Lima, Peru)
A randomised controlled trial of zafirlukast in acute asthma A. Gulati, S. Kabwa, B. K. Jacob (Colchester, Bradford, United Kingdom)
Clinical efficacy of leukotriene antagonist in patients with asthma and allergic rhinitis T. Koga, H. Matsuse, H. Kohrogi, S. Kohno, H. Aizawa (Kurume, Nagasaki, Kumamoto, Japan)
Montelukast and frequency of exacerbations of asthma W. A. Biernacki, S. A. Kharitonov, H. M. Biernacka, P. J. Barnes (London, Gravesend, United Kingdom)
Comparable efficacy of ciclesonide 160 μg once daily and budesonide 200 μg twice daily in patients with asthma P. Niphadkar, K. T. Jagannath, S. Hellbardt, R. Engelstätter (Mumbai, Chennai, India; Konstanz, Germany)
Ciclesonide 80 μg once daily reduces early and late asthmatic reaction, sputum eosinophils and serum ECP in asthma patients challenged with allergens G. M. Gauvreau, R. M. Watson, D. S. Postma, J. D. Monchy, F. Deschesnes, L. P. Boulet, A. Widmann, P. M. O‘Byrne (Hamilton, Quebec City, Canada; Groningen, Netherlands; Konstanz, Germany)
Ciclesonide 80 μg or 160 μg once daily is comparable to fluticasone propionate 88 μg twice daily in the treatment of asthma patients H. Magnussen, J. Hofman, B. Novakova, B. Kaczmarek, M. Hellwig, R. Engelstätter (Grosshansdorf, Konstanz, Germany; Bialystok, Lodz, Poland; Trutnov, Czech Republic)
In vitro metabolism of ciclesonide, beclomethasone dipropionate, budesonide and fluticasone propionate in human precision-cut lung slices R. Nave, R. Fisher, K. Zech (Konstanz, Germany; Tucson, United States Of America)
Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide R. Engelstätter, A. Escher, D. Häfner (Konstanz, Germany)
Uptake, retention and metabolism of ciclesonide in human alveolar epithelial cells R. Nave, H. Sato, T. Nonaka, T. Mochiduki, S. Takahama, S. Kondo (Konstanz, Germany; Tokyo, Japan)